Dotti vs Vivelle-Dot: Same Dose, Smaller Patch — What Actually Changed

Best for you / not for you

Before we go further

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider.

The 30-second verdict

Is Dotti the same as Vivelle-Dot?

Dotti and Vivelle-Dot are both prescription estradiol transdermal systems — skin patches that release the hormone estradiol into the bloodstream. Dotti is approved as a generic of Vivelle-Dot under ANDA 211293 and is labeled by Amneal Pharmaceuticals, with US marketing beginning February 4, 2019. Vivelle-Dot is the brand, approved under NDA 020538, packaged by Sandoz Inc. and manufactured by Noven Pharmaceuticals. They contain the same active drug in the same five strengths.

Two terms, then we move on. The whole argument turns on them.

An NDA (new drug application) is what a company files to get a brand-new drug approved. Vivelle-Dot has one: NDA 020538.

An ANDA (abbreviated new drug application) is the pathway for a generic. It skips new efficacy trials. Instead the company must prove bioequivalence — that its version delivers the same amount of drug into the bloodstream, at the same rate, as the reference product. Dotti has one: ANDA 211293.

So Dotti is a real, FDA-approved generic. Your pharmacist was not lying to you.

The “authorized generic” mix-up

Dotti is sometimes described online as if it were literally the brand patch in a plain box. That isn't correct, and the difference matters to you.

An authorized generic is the brand-name product sold without the brand name, under the brand's own application. Same factory, same patch, plain box. Nothing changes but the label.

Dotti isn't that. Dotti is approved under its own ANDA, and FDA's drug listings name Amneal Pharmaceuticals as the labeler — not Sandoz, not Noven. It's a separately developed product that had to prove it matched.

Here's what a real authorized generic looks like, for contrast. Noven makes a twice-weekly patch called Minivelle. Noven's own website says that in November 2018 it launched an authorized generic of Minivelle, sold simply as “Estradiol Transdermal System,” through Grove Pharmaceuticals, its authorized generic division, and distributed by Prasco.

Same company. Same patch. Plain box. That is an authorized generic. Dotti is a different animal — and it's a different-looking patch, which is exactly why you're here.

Take ten seconds and check your box

The first five digits of the NDC number on the carton tell you which company made what's inside.

Go look. Then come back — because the next number is the one you actually want.

Dotti vs Vivelle-Dot: what actually changed, side by side

At every one of the five strengths, the Dotti patch has a smaller sticking surface than Vivelle-Dot and contains less total estradiol.At the common 0.05 mg/day strength, Vivelle-Dot is a 5.0 cm² patch holding 0.78 mg of estradiol, while Dotti is a 3.78 cm² patch holding 0.627 mg. Both are labeled to deliver 0.05 mg of estradiol per day. These figures come from each product's FDA prescribing information.

You noticed the patch was smaller. You were right. Here is exactly how much smaller.

Table 1 — Patch size and drug content, strength by strength

Sizes and drug amounts: Dotti and Vivelle-Dot prescribing information, DailyMed. Percentage differences: The HRT Index calculation.

So when a woman writes in a review that her new patch is smaller and the box says less estradiol, she has read her own label correctly. That is not a conspiracy theory. That is the printed specification.

Table 2 — What's the same, what's different

Both prescribing informations, DailyMed.

Read the adhesive row twice. The sticky ingredients are the same list. Plenty of women online say Dotti uses “a different adhesive.” Strictly speaking, the labeled adhesive components match, ingredient for ingredient.

What genuinely differs is the backing — the film on top. Vivelle-Dot uses a translucent polyolefin film. Dotti uses polyester with ethylene vinyl acetate copolymer. A different material sitting on top of the same glue, on a patch that's a quarter smaller.

Now read the last row again. Because that's the one that surprised us.

The one thing we can't tell you

Here it is, and we're not going to dress it up.

We cannot tell you whether Dotti works less well for you than Vivelle-Dot. Nobody can. There is no published head-to-head trial in real patients comparing the two.

That much we expected. Dotti's prescribing information says it plainly: there were no clinical trials conducted with Dotti. Approval rested on bioequivalence — blood-level testing showing the drug arrives the same way.

Then we opened Vivelle-Dot's label and read the matching section.

“There were no clinical trials conducted with Vivelle-Dot.”

Vivelle-Dot is bioequivalent to Vivelle — the original, larger estradiol patch, the one that was actually studied in women. Vivelle-Dot's own label describes it as the revised formulation with smaller system sizes, shown to be bioequivalent to that original.

We kept pulling labels. Minivelle's says there have been no efficacy and safety trials conducted with Minivelle, and that it was shown to be bioequivalent to Vivelle in a pharmacokinetic study.

Here's what that means, and it is not what anyone told you.

The patch has been shrinking for thirty years

Compiled by The HRT Index from four FDA prescribing informations.

Every patch in this family — brand and generic alike — traces its evidence back to trials of a patch almost nobody wears anymore.

So the story you've been told, the one where the brand was carefully studied and the generic was waved through, is not what the labels say. Neither of your two options was tested in its own efficacy trial. They both rest on the same measurement: does the estradiol show up in the blood the same way?

That's not a scandal. It's how the FDA has regulated transdermal patches for decades, and it's a reasonable standard. But it means the difference between Dotti and Vivelle-Dot is much smaller than the brand-versus-generic framing suggests — and the certainty anyone can offer you is smaller than you were led to believe.

One more thing, in the fine print

Both labels report how well the patch sticks. Vivelle-Dot's says that across 3 short-term clinical trials with 471 observations, 85% of patches adhered completely over the 3.5-day wear, and 3% detached and were reapplied or replaced.

Dotti's label reports adhesion too. Same 3 trials. Same 471 observations. Same 85%. Same 3%.

Compare that to Minivelle, whose label reports its own adhesion study — 208 observations, a different wear period, its own detachment count. Minivelle tested its patch and printed the result. Dotti's printed adhesion figures are inherited.

Now the fair half, because this cuts both ways.

FDA's guidance for generic transdermal systems recommends that companies assess how well the patch adheres, and separately addresses skin irritation and sensitization studies. That guidance notes a company may evaluate adhesion and blood-level bioequivalence in a single study. Dotti was approved under that framework. Those study results sit in the ANDA file at FDA. They are simply not printed in the label you can read.

So why are we telling you this instead of giving you a verdict? Because a verdict would be a guess, and you have had enough people guess at you. What we can hand you is four labels, opened to the same page, with the arithmetic done. That's more than the pharmacy counter gave you.

Why does Dotti hold 20% less estradiol but deliver the same dose?

An estradiol patch is not a syringe that empties into you. It's a matrix system— the hormone is dissolved inside the sticky layer itself, and it crosses into your skin because it's more concentrated in the patch than in you. Only a fraction of the drug ever leaves. That's why the milligrams printed on the box and the milligrams you absorb per day are two completely different numbers.

Think of a tea bag, not a water bottle. A water bottle holds 500 mL. Drink it, you get 500 mL. Simple.

A tea bag doesn't work that way. It's packed with far more leaf than will ever dissolve. What ends up in your cup depends on how tightly the leaf is packed, how much surface touches the water, and how long it steeps. Two tea bags can be different sizes, hold different amounts of leaf, and still make an identically strong cup — if one is packed tighter.

That's what's happening here. And this is where our arithmetic starts.

Table 3 — The delivery math

Derived by The HRT Index from label values. Identical at all five strengths, since both labels state the composition per unit area is the same across strengths.

So the smaller patch isn't a cheaper patch with less medicine in it. It's a denser patch, engineered to move more hormone through less skin. Same tea, tighter bag.

That's the answer to the question that brought you here. Less estradiol in the patch does not mean less estradiol in you.

The honest asterisk

Look at that third row again. Dotti empties roughly 28% of its drug over a wear period. Vivelle-Dot empties roughly 22%.

Some women report a drop-off on day three. If that effect is real for some people, this row is the only place in the physics where it could live — a patch running closer to the bottom of its supply as the wear period ends.

We want to be blunt: that is a hypothesis, not a finding. Nobody has tested it. The bioequivalence review looked at estradiol blood levels across the wear period and found them equivalent. We're showing you the mechanism that would explain the complaints if the complaints turn out to be about the product. We are not claiming they are.

And Vivelle-Dot's own label makes an unusually candid point here: a serum estrogen level doesn't predict how any individual woman will respond, and comparing drug exposure across different estrogen products to infer safety or effectiveness for one woman may not even be valid.

The label is telling you the same thing we are. Population data can't settle your case.

I switched to Dotti and my symptoms came back. Am I imagining it?

No — your symptoms are real. But patient reviews cannot tell you whether the patch caused them. Bioequivalence is a population standard: it means average blood levels matched, not that every individual will feel identical. And many negative Dotti reviews describe a switch the woman did not choose, which distorts what those reviews look like.

Here's the data, with the sample sizes, because the sample sizes are the story.

Table 4 — What patients report (not clinical evidence)

Retrieved July 2026. These are self-selected, unverified reports.

That gap looks damning. Before you treat it as proof, understand what you're looking at.

Very few women pick Dotti on purpose. A pharmacy or an insurer picks it for them. Read the reviews and you'll see it again and again: my plan stopped covering brand. My pharmacy substituted. Insurance will only pay for generic.

Now think about who writes a review after a forced switch. A woman who gets swapped and feels completely fine goes on with her day. She never types a word. A woman who gets swapped and feels awful goes looking for an explanation, lands on a review page at 2 a.m., and writes.

That's selection bias, and it means a 3.9 and a 7.0 are not measuring the same thing. Vivelle-Dot's reviews come largely from women who chose it and stayed. Dotti's come disproportionately from women who were moved without being asked.

We show you this table as a map of a friction point. Not as a finding about the drug.

What women are actually saying

“Pharmacy filled Dotti because my regular estradiol transdermal system was not available.”
— Anonymous patient review, Drugs.com

“Dotti does not work well for me. Doesn't mean it's bad.”
— Anonymous patient review, Drugs.com

“I had the Dotti patch first, and it was awesome, and it stayed on!”
— Anonymous patient review, Drugs.com

Individual, unverified reports from pseudonymous reviewers, included to show the real friction behind this search. They are not evidence that either product is safer, stronger, or more effective, and no result here is typical of anything.

That third quote matters. She did well on Dotti and worse on a different manufacturer's patch. Any page that shows you only the angry reviews is building you a story, not showing you the evidence.

Things that are not the patch

Before you conclude the product failed you, rule these out. Any one of them can look exactly like “the generic is weaker.”

• The patch lifted at the edges or fell off partway through a wear
• A patch change was late by a day
• You hit a stretch of poor sleep, illness, or high stress
• A thyroid medication, antidepressant, or supplement changed
• Your pharmacy switched you again, to a third manufacturer, without telling you
• A shortage caused a gap in refills
• You were placing it on skin with lotion, oil, or moisture

The 14-day log sorts most of this out in two weeks.

Which patch sticks better — Dotti or Vivelle-Dot?

Neither label claims an advantage over the other, and Dotti's adhesion figures are the same numbers printed in Vivelle-Dot's label. What both labels do agree on is how to apply a patch so it stays put: clean, dry, unbroken skin on the trunk — lower abdomen or buttock — never the breasts, never the waistline, pressed with your palm for about 10 seconds, on a fresh spot each time.

This is the single most fixable cause of “my patch isn't working.”

Table 5 — Application rules, straight from the labels

If your patch falls off

Both labels say the same thing, and it's reassuring: reapply the same patch. If it won't stick, put a new patch on a different spot. Either way, stay on your original schedule. Don't shift your change day. Don't wear two.

And a firm one: do not cut, trim, or split an estradiol patch. Neither Dotti's nor Vivelle-Dot's label gives any instruction for cutting a patch, and these are matrix systems, where the drug is dissolved throughout the adhesive. Cutting one changes the releasing surface in a way nobody has measured. If your dose needs to change, ask for the correct strength.

The one physical difference that could matter

If a patch adhered fine for you for years and the new one lifts — or the new one sticks fine and the old one didn't — the backing film is the place to look. Vivelle-Dot uses a translucent polyolefin film. Dotti uses polyester with ethylene vinyl acetate copolymer. Different top layer, different flex, different behavior against a waistband.

We can't tell you which is better. We can tell you it's a real, documented difference, and that “they're identical” isn't an accurate thing for anyone to say to you.

Can my pharmacy switch me to Dotti without asking me?

In most states, a pharmacist may substitute a therapeutically equivalent generic without calling your prescriber.Substitution rules and patient-notification requirements vary by state. The instruction that blocks a substitution is written by your prescriber on the prescription — not requested by you at the counter.

This is the part that makes women feel powerless. It shouldn't. Two different people are making this decision, and they are not the same person:

• Your insurer decides what it will pay for. This is usually the real driver. When a plan stops covering brand, the pharmacy's hands are largely tied.
• Your pharmacist fills what the prescription and the law allow, using what's actually in stock.

Neither is trying to shortchange you. Neither will fix it unless someone asks.

What “DAW” means

DAW stands for “dispense as written.” It's a code the prescriber puts on a prescription. The relevant one tells the pharmacy that no substitution is permitted — the brand must be dispensed. Your prescriber writes it. Not you. That's the lever, and it's the reason the next two scripts exist.

Say this to your pharmacist

Copy it. Read it off your phone. Ninety seconds.

“Can you tell me the exact manufacturer and NDC number of what you dispensed, and print it on my receipt? Was I switched because of my insurance, because of stock, or both? Can you check whether my previous manufacturer is available anywhere in your system? If my prescriber writes it dispense-as-written, can you fill it?”

Write the answers down. That's your evidence.

Say this to your prescriber

“I was stable on ______. Since I was switched to ______ on [date], I've noticed ______. I'm not changing my dose on my own. I've kept a 14-day log. Can we look at whether this is an adhesion problem, a product problem, or a supply problem — and whether a dispense-as-written prescription, a different manufacturer, or a different FDA-approved estradiol route makes sense for me?”

Notice what that message does. It's specific. It's dated. It's not accusatory. It shows you kept records. It hands the clinician a decision instead of an emotion.

That's the message that gets a callback. Save it now, while you're thinking about it.

How do I get brand Vivelle-Dot back?

Two routes exist:a dispense-as-written prescription run through your insurer's prior authorization process, or paying cash. Insurers respond to documentation — a dated symptom timeline tied to the switch — far more than to preference. And at current cash prices, the fight is not always worth having.

Prior authorization means your insurer wants your prescriber to justify the brand before it pays. It's paperwork, not a judgment on you.

What actually moves a prior authorization

Here's a legitimate point most people don't know they have. If your issue is adhesion or skin reaction — not symptom control — you can note that the adhesion data printed in Dotti's label are the same figures printed in Vivelle-Dot's label, from the same trials, rather than results of a head-to-head comparison. That's a factual observation about the labels, and it's a fair thing for a clinician to weigh when documenting why one specific product suits one specific patient's skin.

That is not a claim that Dotti is inferior. It's a claim that the printed data don't speak to your situation. Different sentences. The second one is defensible.

What do Dotti and Vivelle-Dot cost right now?

Generic Dotti costs a fraction of brand Vivelle-Dot,though the gap narrows once discount cards are involved. In July 2026, SingleCare listed brand Vivelle-Dot's retail price at $206.03 for a box of 8 patches at 0.05 mg/day, with a discounted generic at $51.57. Prices vary by pharmacy, strength, and week.

Sometimes the fight costs more than the drug.

Table 6 — Cash price snapshot, 0.05 mg/day, box of 8 patches

Dated snapshots, not quotes. Confirm at your own pharmacy before you decide anything.

The spread between brand retail and a discounted generic is roughly $154 per box. If a prior authorization drags on for eight weeks while your symptoms are back, and brand cash is $206, some women will decide $206 is the cheaper option. That's a legitimate choice, and nobody tells you it's on the table.

Two things that trip people up. First, you cannot stack a discount card with your insurance on the same fill. You pick one. Ask the pharmacist to run both and tell you which is lower. They will.

Second, read the coupon fine print. GoodRx's lowest advertised Dotti price is currently tied to GoodRx Companion, a paid membership, not the free coupon. That's a real price — it just isn't free. Check which number you're actually being quoted.

Affiliate disclosure:The HRT Index may earn a commission if you book through the Midi or Sesame links below. It did not affect the label arithmetic, the shortage table, or the limitations we list for each provider. Two of our affiliate partners are deliberately excluded from this page — we explain why near the bottom.

If you need a prescriber who will actually write it

Read this first, because it will save some of you a wasted click.

No telehealth company can make Vivelle-Dot appear on a pharmacy shelf. If your problem is that nothing is in stock anywhere, a new prescriber does not fix that. A different pharmacy or a different formulation does. Skip ahead to the availability table.

But if your problem is access to someone who will write the prescription and work the insurer, that's a different problem, and there are two reasonable answers.

Table 7 — What each provider states, and what we verified

If you have commercial insurance: Midi Health

Midi is a virtual menopause clinic. Its site states it prescribes FDA-approved hormone therapy, that it's available in all 50 states, and that it's in-network with most PPO plans, with visits and prescriptions in your care plan covered by major insurers. Midi says its care coordinators help patients get HRT covered when a clinician prescribes it.

That last part is the whole reason Midi appears on this page. A prior authorization is a coordination job. Midi does that job.

Midi's chief medical officer, Dr. Kathleen Jordan, told NBC News that her patients are increasingly struggling to fill estrogen patch prescriptions because of pharmacy shortages: “This was happening occasionally last year but has escalated this year.”

Dr. Jordan is Midi's chief medical officer, and we have an affiliate relationship with Midi. We quote her because she is on the record in national press describing the exact problem this page is about — not as evidence that Midi's care works better.

Now the limitation, plainly, because it disqualifies some of you.

Midi does not accept Medicaid or Medi-Cal — its site says it cannot treat Medicaid or Medi-Cal patients at all, not even as self-pay. Midi is also not covered by Medicare; beneficiaries can be seen as self-pay but cannot submit any claims for those visits.

If you're on Medicare or Medicaid, Midi is not your route. Don't spend the appointment fee. Go to your primary care clinician, an in-person women's health practice, or a cash-pay visit — and if you're not sure which, Find My HRT Path will sort it in a few minutes.

Midi's tradeoff is deliberate. Because it focuses on commercial PPO coverage rather than government programs, it can bill visits and prescriptions to insurance across all 50 states — which is exactly the machinery a brand-necessary request needs.

Check coverage before you book. Coverage varies by plan, and deductibles, coinsurance, and copays may still apply.

If you're paying cash, or you need an appointment this week: Sesame

Sesame is a cash-pay marketplace. It states that it does not bill insurance, that visits start at $34, that licensed providers are available in all 50 states, and that a prescription is sent to your preferred pharmacy for same-day pickup. Medication cost is not included in the visit price. Sesame also provides a prescription savings card.

That “your preferred pharmacy” line is why Sesame fits this page. During a shortage, the pharmacy holding your strength may not be your usual one. Being able to route a fresh prescription to a specific pharmacy is worth a great deal.

The limitation, plainly. Sesame does not bill insurance at all. If your goal is getting your insurer to cover brand Vivelle-Dot, a cash-pay visit does not advance that — nobody there will file your prior authorization. Sesame solves speed and access, not coverage. Confirm the visit type, the total price, and the cancellation terms on the checkout screen before you book.

If coverage is the fight you're in, Midi or your own clinician is the right tool. If time is the fight you're in, this is.

Which estradiol patch can I actually get right now?

Availability depends on your exact strength, not on the brand name.Checking ASHP's estradiol transdermal system shortage bulletin in July 2026, Amneal listed several Dotti and Lyllana strengths on back order with no estimated release date, while other Dotti strengths appeared among available products. Noven's presentations were on intermittent back order with weekly releases, and Zydus was on allocation to contracted customers.

Most shortage pages tell you “patches are short.” That's useless when you're standing at a counter. Here's the strength-level picture.

Table 8 — Availability snapshot

Source: ASHP drug shortage bulletin for estradiol transdermal system, checked July 2026. ASHP updates this bulletin frequently and availability changes weekly. Confirm with your pharmacy.

Look at the first two rows again. Your 0.05 mg Dotti was on back order. Your neighbor's 0.0375 mg Dotti was on the shelf. Same brand. Same week. That's why one woman gets switched and another doesn't, and why “is Dotti in shortage” has no single answer.

Why the FDA says there's no shortage

Because the FDA and the pharmacists are counting different things. This is the part that makes women feel gaslit, and it has a clean explanation.

Look up FDA's drug shortage database and you may find nothing about estradiol patches. An FDA spokesperson told CNBC in June 2026 that estradiol patches are not currently in shortage, and that all six manufacturers report producing at full capacity while working to keep up with demand.

Meanwhile ASHP lists multiple estradiol patch products on back order. Both are telling the truth. They count different data.

ASHP's senior director of pharmacy practice and quality, Michael Ganio, explained the gap to CNBC: because the FDA can't easily track prescriptions that go unfilled, or count the prescribers who quietly switched patients to something else, it is very hard for the agency to measure true demand.

So the factories run flat out. The FDA sees full production and declares no shortage. Your pharmacy still has nothing on the shelf. You are not imagining the empty shelf. It just isn't being counted.

Why demand exploded

The FDA moved to remove the boxed warnings from menopausal hormone therapy in November 2025. Prescriptions climbed fast. Only a handful of companies make estradiol patches — Noven, Sandoz, Viatris/Mylan, Amneal, and Zydus — and patches are far harder to manufacture than pills.

The scale, from Truveta, a health analytics company drawing on an electronic health record database covering more than 130 million patients across all 50 states, as reported by Reuters in April 2026:

Sandoz told Reuters that the FDA's November action “created unprecedented demand that cannot fully be met at present,” and said it has shipped additional supplies to the US. Estrogen patches are generic medicines with thin profit margins, which gives manufacturers little incentive to build new production lines quickly — and new facilities take years. Industry sources told Reuters the scramble could last up to three years.

A number you'll see everywhere, that we're not repeating. Several sites cite a “72% demand surge.” We could not trace it to any primary source; the sites cite each other. The four figures above are traceable.

If your pharmacy is out

1. Ask whether your same strength is available from a different manufacturer. Often it is.
2. Ask whether Vivelle-Dot is in stock and what your plan would require.
3. Ask your prescriber whether a manufacturer-specific prescription is appropriate.
4. Ask whether a different FDA-approved estradiol route — gel, spray, ring, or tablet — fits you.
5. Refill 5 to 7 days early when you can. Build a buffer before you need one.
6. Do not stretch a patch to five days, cut one, wear two, or skip. Not once. Call instead.

Do Dotti and Vivelle-Dot still have a boxed warning in 2026?

As of our last check, yes— both still carry the older boxed warning. On February 12, 2026, the FDA approved updated labeling for six menopausal hormone therapy products, removing the risk statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning. No estradiol patch was in that first batch.

Here's the timeline, from the FDA and HHS directly:

• November 10, 2025 — HHS and the FDA announce they are initiating removal of the boxed warnings on cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products. The FDA asks companies to file labeling changes. It does not seek to remove the endometrial cancer boxed warning for systemic estrogen-alone products.
• 29 drug companies submit proposed labeling changes at the FDA's request.
• February 12, 2026 — the FDA approves the first batch: six products.

Which six? Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. Not one estradiol patch. Not Dotti. Not Vivelle-Dot. Not Climara, Minivelle, or Lyllana.

Vivelle-Dot's prescribing information on DailyMed still carries the full boxed warning, on a label last revised in November 2023. Dotti's still carries it, last revised May 2024.

Read this correctly, because it's easy to get wrong. This is a paperwork status, not a safety signal. It does not mean the FDA thinks patches are riskier than the six updated products. It means the label change is rolling out in batches and your patch's turn hasn't come. The agency started this across the whole class.

Practically: if you compare the paper insert in a Dotti box against a friend's Prometrium insert this month, you'll see two different boxed warnings for drugs in the same class. Now you know why.

What is staying for systemic estrogen-alone products, including these patches: the boxed warning about endometrial cancer. If you still have a uterus and take estrogen by itself, unopposed, that risk is real and the warning stays.

Do you need progesterone with your patch?

If you still have a uterus and use a systemic estradiol patch, you generally need a progestogen— progesterone or a progestin — alongside it to protect the lining of your uterus. This does not change when your patch brand changes. Vivelle-Dot's label states that when estrogen is prescribed for a postmenopausal woman with a uterus, adding a progestogen should be considered to reduce the risk of endometrial cancer.

Estrogen alone thickens the uterine lining. A progestogen counters that. Women who've had a hysterectomy generally don't need one.

We raise it here for one specific reason. When a substitution happens, prescriptions get shuffled. Refills fall out of sync. A woman focused on chasing down her estrogen patch can lose track of whether her progesterone refill ever went through. Check. It takes one look at your pharmacy app.

The 60-second refill audit

The whole estradiol patch family, compared

Five twice-weekly estradiol patches share the same five delivery strengths but differ in size, drug load, and manufacturer.Minivelle is the smallest at 3.30 cm² for the 0.05 mg/day strength, yet holds more estradiol than either Dotti or Vivelle-Dot. Dotti and Lyllana, both from Amneal, have identical label specifications at every strength. Climara is a once-weekly patch worn on a completely different schedule.

If a pharmacist offers you a different name, this tells you what you're being handed.

Table 9 — Twice-weekly patches at 0.05 mg/day

Sizes and drug amounts from each product's prescribing information, DailyMed. Drug load: The HRT Index calculation. Climara (Bayer) is once-weekly and sized differently.

Two things fall out of that table that nobody tells you.

First, Dotti and Lyllana are the same patch design. Identical surface area, identical estradiol content, identical three-layer construction, same NDC prefix, same company. Coverage policies may still group them differently — one insurer pairs Lyllana with Minivelle and Dotti with Vivelle-Dot — but a generic doesn't have to match its reference product's dimensions. Check your box, not a formulary.

Second, look at Minivelle. It's the smallest patch here — smaller than Dotti — and it holds more estradiol than either Dotti or Vivelle-Dot at the same strength. Its drug is packed more than 60% tighter than Vivelle-Dot's.

Which kills a tempting theory. If “smaller patch, less drug” meant “weaker,” Minivelle should be the strongest of the bunch. It isn't. It's a different design hitting the same delivery target.

Patch size tells you nothing about your dose. The only number that describes your dose is the mg/day on the box.

What if I need to leave the patch entirely?

FDA-approved alternatives that keep the transdermal route include estradiol gels and a transdermal spray, which — like patches — bypass first-pass liver metabolism. Oral estradiol is widely available and inexpensive but is processed by the liver first. Vaginal estrogen treats genitourinary symptoms, not hot flashes. Any switch changes dose equivalence and should be made with a prescriber.

Why does the route matter? Because a pill passes through your liver before it reaches the rest of you, and that changes clotting proteins. A patch, gel, or spray goes straight into the bloodstream through skin.

The Menopause Society's 2022 position statement puts it this way: transdermal routes and lower doses of hormone therapy may decrease the risk of venous thromboembolism — a blood clot — and stroke. The same statement finds that for most healthy symptomatic women under 60 and within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks.

If you were put on a patch specifically because of clot risk, migraine history, or liver concerns, say so before anyone suggests a pill.

Here's the practical catch nobody warns you about. Dr. Lauren Streicher, a professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, has said gels, creams, and patches are all equal on safety — they're all transdermal. But she also points out that the non-patch options are less likely to be covered by insurance.

So a gel may be the easiest FDA-approved product to find during a shortage, and the most expensive one at the counter. Ask your pharmacist to price it before your prescriber sends it over.

About compounded hormones — read this before someone sells you one

You will encounter this. During a shortage, pages appear arguing that a compounded hormone product is a better, more “natural” route than a patch, sometimes with a discount code attached. We've watched it happen with this exact shortage.

Compounded preparations are mixed by a compounding pharmacy. They are not FDA-approved. They are not reviewed by the FDA for dose consistency, and they are not shown to be equivalent to Dotti, Vivelle-Dot, or any FDA-approved product.

The Menopause Society's 2022 position statement is direct: compounded bioidentical hormone therapy presents safety concerns and is not recommended.

And here's something telling. Sesame — a company we have an affiliate relationship with, and which we recommend above — says on its own menopause page that compounded bioidentical hormone therapy is prescribed and dispensed outside of formal FDA regulation and standardization, and that studies have not shown it to be safer or more effective than conventional hormone therapy.

When a company that could profit from selling you something tells you the evidence isn't there, believe them.

If an FDA-approved patch, gel, or spray works for you, there is no evidence-based reason to leave it for a compounded product. “More natural” is a marketing phrase. It is not a regulatory status, and it is not a clinical finding.

\ud83d\udd0e So what should you actually do?

Find your row.

Not sure which row is yours? That's precisely what the tool is for.

It also tells you when online care isn't the right starting point — which is worth knowing before you pay for a consult.

Who should not sort this out online

Estradiol patches carry real contraindications, and a pharmacy substitution is a bad moment to self-manage.Dotti's and Vivelle-Dot's labels list identical contraindications, including undiagnosed abnormal genital bleeding, breast cancer or a history of it, estrogen-dependent tumors, active or prior blood clots in the legs or lungs, active arterial clotting disease such as stroke or heart attack, known clotting disorders, and liver impairment or disease.

Call a clinician now — not a website — if you have:

• Vaginal bleeding after menopause that hasn't been evaluated
• A history of breast cancer or an estrogen-dependent cancer
• A history of blood clots, stroke, or heart attack
• A known clotting disorder such as protein C, protein S, or antithrombin deficiency
• Liver disease

None of this means you can't be on hormone therapy. It means the decision isn't one a comparison page — including this one — should be making for you.

How The HRT Index verified this page

This comparison was built under The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule.

What we actually verified

What we did not verify, and won't pretend to

• We did not test the patches.
• We did not interview patients.
• We commissioned no study.
• No clinician reviewed this page. It is editorial research. We say so at the top.
• We cannot verify your pharmacy's stock, your insurance coverage, or how your body absorbs a specific product.
• We do not know whether Dotti works less well for you. Neither does anyone else.

Why two of our affiliate partners are missing from this page

We have affiliate relationships with Winona and Inner Balance (Oestra). Neither appears as a recommendation here.

Both are compounded providers. Neither can supply Dotti or Vivelle-Dot. Under our FDA-Approved Override rule, compounded providers are never featured as recommendations on FDA-approved brand pages — regardless of what we're paid.

We tell you this because a page arguing about label precision has no business being vague about its own incentives.

Affiliate disclosure: The HRT Index may earn a commission when you book through links on this page. It doesn't change what we found in the labels, and it didn't change what we wrote.

The HRT Index evaluates providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access.

The bottom line

Your pharmacy gave you a different patch. It's smaller. It holds less drug. Both of those things are printed on the label, and both are true.

It's also true that the FDA reviewed the blood-level data and found the two deliver the same daily dose — and that the smaller patch does it by packing its estradiol about 6% more densely and moving it about 32% harder through less skin.

And it's true that neither patch, brand or generic, was ever tested in its own efficacy trial. They both point back to the same original. Nobody has run the study that would tell you how you will do on either one.

You are not crazy. You were not necessarily cheated. You were handed a real medical product with real differences and told, in eight seconds at a counter, that nothing had changed.

Something changed. Now you know exactly what. Keep the log. Ask the two questions. Bring the numbers.